The FDA sent an early safety alert warning clinicians of deployment failures with certain Boston Scientific AXIOS Stent and ...

Boston Scientific said it will pay $374 a share in cash and stock for Penumbra, which makes products to remove blood clots ...

Boston Scientific agreed to buy medtech firm Penumbra in a $14.5  billion deal on Thursday, its second‑largest takeover ever, ...

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes ...

Penumbra shares soared 12% to $351.46 on Thursday. Boston Scientific stock slumped 4.1%, making it one of the worst ...

Boston will inherit products, including Penumbra’s Lightning thrombectomy systems, to advance its vascular care provision.

Boston Scientific’s $374/share Penumbra deal boosts mechanical thrombectomy exposure and growth. Click here to learn more ...

Boston Scientific to buy Penumbra for $14.5B, expanding neurovascular thrombectomy, with long-term margin gains. Click here ...

Boston Scientific (NYSE:BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker ...

Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...

Boston Scientific to acquire thrombectomy firm Penumbra for $14.5bn, expanding its cardiovascular portfolio as deal reshapes ...

Boston Scientific (NYSE: BSX) announced that it received CE mark approval for its Embold detachable coil system.